Glutamine supplementation for critically ill adults

Tao, Kun‐Ming; Li, Xiaoqian; Yang, Liqun; Yu, Weifeng; Lu, Zhijie; Sun, Yuming; Wu, Feixiang

doi:10.1002/14651858.cd010050

Cited by 22 publications

(36 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In regard to side effects, only 11 of the 22 meta-analyses (50%) addressed this topic with six of them noting that no side effects were observed (12)(13)(14)19,24,26), and the remaining five meta-analyses all mentioned the REDOX study that indicated that critically ill patients with glutamine doses of >0.5 g/kg/day had higher urea concentrations and higher mortality rates (20)(21)(22)32). However, it has been noted that there were problems with the REDOX study as 30% of the patients in the glutamine supplementation group were shown to have baseline renal failure at admission, which is a very common exclusion criteria for the majority of glutamine supplementation clinical trials (16,21).…”

Section: Discussionmentioning

confidence: 99%

“…For the majority of the meta-analyses (11 of the 22), the number of clinical studies entered for analysis ranged between 10 and 20. There were five meta-analyses that used <6 clinical studies, and one meta-analysis published in 2014 used 53 clinical studies, and these six analyses represent 43% of the 125 unique clinical studies used by all 22 meta-analyses (20). Of the 125 unique clinical studies used by the 22 meta-analyses in this umbrella review, 57 (46%) were used only once.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic benefits of glutamine: An umbrella review of meta-analyses

McRae

2017

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Glutamine may be an essential amino acid in patients with catabolic disease, as it has been demonstrated that circulating glutamine levels drop during critical illness and following major surgery; this may result in an increase in secondary infection risk, recovery time and mortality rates. However, there is much discrepancy in the literature with regards to randomized controlled studies, and therefore, the present study is an umbrella review of published meta-analyses, conducted to examine the effectiveness of glutamine's role as a therapeutic agent. A search using PubMed, Cochrane Library and CINAHL from January 1st, 1980 to December 31st, 2016 was conducted using the following strategy: 'Glutamine AND (meta-analysis OR systematic review)' and publications were retrieved, which provided quantitative statistical analysis of pooled treatment effects on the relative risks of infectious complications, mortality and length of stay in hospital. A total of 22 meta-analyses were entered into the current umbrella review. As displayed in Tables I, II and III, these analyses are split into three groups, based on different parameters. Of the 19 meta-analyses investigating the effects of infectious complications, 15 identified statistically significant reductions in complications, with relative risks ranging between 0.42 and 0.93. In addition, 12 of the 18 meta-analyses analyzing the length of hospital stays presented statistically significant reductions in the length of stay, with reductions ranging between 0.19 to 4.73 days. Only 4 of the 15 meta-analyses studying mortality effects identified statistically significant reductions in mortality with relative risks ranging between 0.64 and 1.28. Statistically significant heterogeneity was observed in 16 of 22 meta-analyses, and publication bias was observed in five of 11 meta-analyses. Glutamine supplementation for critically ill or surgical patients through parenteral or enteral routes appears to reduce the rate of hospital acquired infectious complications and shortening of the length of stay in hospital. Furthermore, glutamine supplementation appeared to reduce the rate of in-patient mortality, but the majority of meta-analyses did not reach statistical significance. However, researchers must appreciate the positive results with caution in light of the fact that there exists statistically significant heterogeneity for the majority of meta-analyses, and statistically significant publication bias in almost half.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Therapeutic benefits of glutamine: An umbrella review of meta-analyses

McRae

2017

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…It is pointed out that studies involving patients on enteral nutrition and with an enterally administered supplementation are less likely to show beneficial effects from glutamine supplementation [7–10]. However, when separating studies employing glutamine supplementation by the parenteral route only, there is still one meta-analysis advocating the use of glutamine supplementation in this setting [9].…”

Section: Glutamine Is Not For Everybody But Possibly For Somementioning

confidence: 99%

Is the glutamine story over?

Smedberg

Wernerman

2016

Crit Care

View full text Add to dashboard Cite

Glutamine has been launched as a conditionally indispensible amino acid for the critically ill. Supplementation has been recommended in guidelines from international societies. Although data have been presented pointing out that glutamine supplementation may not be for everybody, recommendations for treatments and design of study protocols have included all critically ill patients. Results from more recent studies and meta-analyses indicate that indiscriminate use of glutamine supplementation in critically ill patients may actually cause harm rather than beneficial effects. This viewpoint sorts out arguments of controversy in the glutamine story.

show abstract

“…Польза и эффективнось энтерального питания, обогащенного глютамином, была оценена в нескольких метаанализах и рандомизированных иссле-дованиях у больных в критическом состоянии, в большин-стве из которых не было зарегистрировано ни одного убедительного снижения показателей смертности или уменьшения инфекционных осложнений [20][21][22][23]. Кроме того, в одном большом многоцентровое рандомизиро-ванном исследовании глютамина данной группы больных сообщили о потенциальном вреде с тенденцией к увели-чению 28-дневной смертности у пациентов, получавших энтеральное питание, обогащенное глютамином [24].…”

Section: составunclassified

Enteral Nutrition After Advadvanced Combined Operative Interventions in Oncosurgery

Нехаев¹,

Сытов²,

Ломидзе³

2016

Med. sov.

View full text Add to dashboard Cite

Энтеральное питание (ЭП) -тип лечебного или дополнительного питания специальными смесями, при котором всасыва-ние пищи (при ее поступлении через рот, через зонд в желудке или кишечнике) осуществляется физиологически адекват-ным путем, то есть через слизистую оболочку желудочно-кишечного тракта. В данном обзоре будут рассмотрены такие аспекты энтерального питания (ЭП) у больных, находящихся в отделениях реанимации и интенсивной терапии (ОРИТ), как состав, компоненты, способы доставки, осложнения ЭП.

show abstract

Glutamine supplementation for critically ill adults

Cited by 22 publications

References 23 publications

Therapeutic benefits of glutamine: An umbrella review of meta-analyses

Therapeutic benefits of glutamine: An umbrella review of meta-analyses

Is the glutamine story over?

Enteral Nutrition After Advadvanced Combined Operative Interventions in Oncosurgery

Contact Info

Product

Resources

About